CD8+ cell noncytotoxic anti-HIV response

CD8+ cell noncytotoxic anti-HIV response appears to be an anti-HIV innate immune response because it can be observed in vitro with CD8+ cells from unexposed and uninfected healthy individuals.[1]

The presence of a CD8+ cell noncytotoxic anti-HIV response (CNAR) was first reported in 1986 by researchers in the laboratory of Dr. Jay Levy at the University of California San Francisco (UCSF).[2] It was recognized that CD8+ cells from HIV-infected individuals can suppress HIV replication without directly killing the infected cells.

CNAR was originally hypothesized to be mediated by a CD8+ cell anti-HIV factor (CAF). It is now known that CNAR is mediated by multiple secreted proteins or 'soluble factors', including beta-chemokines (MIP-1 alpha, MIP-1 beta, and RANTES)[3] and type I interferons (interferon alpha and interferon beta).[4]

References

  1. ↑ Levy, Jay A. (2007), HIV and the pathogenesis of AIDS (3 ed.), Wiley-Blackwell, p. 209, ISBN 978-1-55581-393-2
  2. ↑ Walker CM, Moody DJ, Stites DP, Levy JA (1986). "CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication". Science. 234 (4783): 1563–6. Bibcode:1986Sci...234.1563W. doi:10.1126/science.2431484. PMID 2431484.
  3. ↑ Cocchi, Fiorenza; DeVico, Anthony L.; Garzino-Demo, Alfredo; Arya, Suresh K.; Gallo, Robert C.; Lusso, Paolo (1995-12-15). "Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells". Science. 270 (5243): 1811–1815. Bibcode:1995Sci...270.1811C. doi:10.1126/science.270.5243.1811. ISSN 0036-8075. PMID 8525373.
  4. ↑ Killian, M. Scott; Teque, Fernando; Walker, Robert L.; Meltzer, Paul S.; Killian, J. Keith (November 2013). "CD8+ Lymphocytes Suppress Human Immunodeficiency Virus 1 Replication by Secreting Type I Interferons". Journal of Interferon & Cytokine Research. 33 (11): 632–645. doi:10.1089/jir.2012.0067. ISSN 1079-9907. PMC 3814821. PMID 23402527.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.